Surfactant Treatment at Birth in a Contemporary Cohort of Preterm Infants with Bronchopulmonary Dysplasia

Overview

Journal J Perinatol

Specialty Gynecology & Obstetrics

Date 2024 Jul 17

PMID 39020028

Authors

Clifford Mueller

Edward G Shepherd

Matthew J Kielt

Sara Conroy

Erik A Jensen

Nicolas A Bamat

Howard Panitch

Jon Levin

Milenka Guaman Cuevas

William Truog

Steven H Abman

Leif D Nelin

Affiliations

Soon will be listed here.

Abstract

Objective: Initial surfactant studies demonstrated improvements in survival and need for respiratory support. However, as the use of non-invasive respiratory support has increased the use of surfactant has decreased. We examined in a contemporary cohort of BPD patients if surfactant use was associated with BPD severity.

Study Design: An observational study using data from the BPD Collaborative Registry.

Results: 971 infants with BPD met entry criteria, 864 (89%) had received surfactant in the first 72 h of life (SURF) and the remainder had not (no surfactant). There was an association between SURF and BPD grade, with a greater likelihood of grade 3 BPD in infants who received surfactant in the DR or who had 2 or more doses.

Conclusions: We speculate that the use of surfactant in the DR and use of multiple doses reflect the impact of perinatal factors beyond immaturity alone that increase the risk for grade 3 BPD.

References

NORTHWAY Jr W, ROSAN R, Porter D . Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967; 276(7):357-68. DOI: 10.1056/NEJM196702162760701. View

Tracy M, Berkelhamer S . Bronchopulmonary Dysplasia and Pulmonary Outcomes of Prematurity. Pediatr Ann. 2019; 48(4):e148-e153. DOI: 10.3928/19382359-20190325-03. View

Jensen E, Schmidt B . Epidemiology of bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol. 2014; 100(3):145-57. PMC: 8604158. DOI: 10.1002/bdra.23235. View

Thebaud B, Goss K, Laughon M, Whitsett J, Abman S, Steinhorn R . Bronchopulmonary dysplasia. Nat Rev Dis Primers. 2019; 5(1):78. PMC: 6986462. DOI: 10.1038/s41572-019-0127-7. View

Dumpa V, Bhandari V . Surfactant, steroids and non-invasive ventilation in the prevention of BPD. Semin Perinatol. 2018; 42(7):444-452. DOI: 10.1053/j.semperi.2018.09.006. View

Jobe A . The new BPD: an arrest of lung development. Pediatr Res. 1999; 46(6):641-3. DOI: 10.1203/00006450-199912000-00007. View

Isayama T, Lee S, Yang J, Lee D, Daspal S, Dunn M . Revisiting the Definition of Bronchopulmonary Dysplasia: Effect of Changing Panoply of Respiratory Support for Preterm Neonates. JAMA Pediatr. 2017; 171(3):271-279. DOI: 10.1001/jamapediatrics.2016.4141. View

Poindexter B, Feng R, Schmidt B, Aschner J, Ballard R, Hamvas A . Comparisons and Limitations of Current Definitions of Bronchopulmonary Dysplasia for the Prematurity and Respiratory Outcomes Program. Ann Am Thorac Soc. 2015; 12(12):1822-30. PMC: 4722827. DOI: 10.1513/AnnalsATS.201504-218OC. View

Hines D, Modi N, Lee S, Isayama T, Sjors G, Gagliardi L . Scoping review shows wide variation in the definitions of bronchopulmonary dysplasia in preterm infants and calls for a consensus. Acta Paediatr. 2016; 106(3):366-374. DOI: 10.1111/apa.13672. View

10.

Jobe A, Bancalari E . Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001; 163(7):1723-9. DOI: 10.1164/ajrccm.163.7.2011060. View

11.

Jensen E, Dysart K, Gantz M, McDonald S, Bamat N, Keszler M . The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach. Am J Respir Crit Care Med. 2019; 200(6):751-759. PMC: 6775872. DOI: 10.1164/rccm.201812-2348OC. View

12.

Abman S, Collaco J, Shepherd E, Keszler M, Cuevas-Guaman M, Welty S . Interdisciplinary Care of Children with Severe Bronchopulmonary Dysplasia. J Pediatr. 2016; 181:12-28.e1. PMC: 5562402. DOI: 10.1016/j.jpeds.2016.10.082. View

13.

Guaman M, Pishevar N, Abman S, Keszler M, Truog W, Panitch H . Invasive mechanical ventilation at 36 weeks post-menstrual age, adverse outcomes with a comparison of recent definitions of bronchopulmonary dysplasia. J Perinatol. 2021; 41(8):1936-1942. PMC: 8342304. DOI: 10.1038/s41372-021-01102-w. View

14.

Jensen E, Edwards E, Greenberg L, Soll R, Ehret D, Horbar J . Severity of Bronchopulmonary Dysplasia Among Very Preterm Infants in the United States. Pediatrics. 2021; 148(1). PMC: 8290972. DOI: 10.1542/peds.2020-030007. View

15.

Sardesai S, Biniwale M, Wertheimer F, Garingo A, Ramanathan R . Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future. Pediatr Res. 2016; 81(1-2):240-248. DOI: 10.1038/pr.2016.203. View

16.

Gallacher D, Hart K, Kotecha S . Common respiratory conditions of the newborn. Breathe (Sheff). 2016; 12(1):30-42. PMC: 4818233. DOI: 10.1183/20734735.000716. View

17.

Lane M, Kishnani S, Udemadu O, Danquah S, Treadway 3rd R, Langman A . Comparative efficacy and safety of late surfactant preparations: a retrospective study. J Perinatol. 2021; 41(11):2639-2644. PMC: 8290378. DOI: 10.1038/s41372-021-01142-2. View

18.

Ramanathan R, Rasmussen M, Gerstmann D, Finer N, Sekar K . A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol. 2004; 21(3):109-19. DOI: 10.1055/s-2004-823779. View

19.

Lee S, Beltempo M, McMillan D, Seshia M, Singhal N, Dow K . Outcomes and care practices for preterm infants born at less than 33 weeks' gestation: a quality-improvement study. CMAJ. 2020; 192(4):E81-E91. PMC: 6989018. DOI: 10.1503/cmaj.190940. View

20.

Govindaswami B, Nudelman M, Narasimhan S, Huang A, Misra S, Urquidez G . Eliminating Risk of Intubation in Very Preterm Infants with Noninvasive Cardiorespiratory Support in the Delivery Room and Neonatal Intensive Care Unit. Biomed Res Int. 2019; 2019:5984305. PMC: 6348842. DOI: 10.1155/2019/5984305. View